Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Spigel DR
- Vicente D
- Ciuleanu TE
- Gettinger S
- Peters S
- Horn L
- Audigier-Valette C
- Aranda NP
- Cheng Y
- Zhang H
- Shi M
- Luft A
- Wolf J
- Antonia S
- Nakagawa K
- Fairchild J
- Baudelet C
- Pandya D
- Doshi P
- Chang H
- Reck M
Grupos
Abstract
Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase 1/2 data show activity of nivolumab in previously treated SCLC.
Datos de la publicación
- ISSN/ISSNe:
- 0923-7534, 1569-8041
- Tipo:
- Article
- Páginas:
- 631-641
- PubMed:
- 33539946
- Factor de Impacto:
- 8,590 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ANNALS OF ONCOLOGY ELSEVIER
Citas Recibidas en Web of Science: 248
Documentos
- No hay documentos
Filiaciones
Keywords
- PD-1, biomarkers, immunotherapy, small-cell lung cancer
Campos de Estudio
Cita
Spigel DR,Vicente D,Ciuleanu TE,Gettinger S,Peters S,Horn L,Audigier C,Aranda NP,JUAN O,Cheng Y,Zhang H,Shi M,Luft A,Wolf J,Antonia S,Nakagawa K,Fairchild J,Baudelet C,Pandya D,Doshi P,Chang H,Reck M. Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. Ann. Oncol. 2021. 32. (5):p. 631-641. IF:51,769. (1).
Portal de investigación